The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
|Videos|June 1, 2013
Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma
Author(s)Richard D. Carvajal, MD
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.
Advertisement
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition using the agent selumetinib in patients with advanced uveal melanoma.
The trial exploring selumetinib was the first to discover an effective agent for patients with advanced uveal melanoma. Even though the MEK inhibitor trametinib was recently approved, Carvajal believes clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.
<<<
Advertisement
Related to this article
Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across 3 cohorts in resectable locally advanced HNSCC.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma
5